OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis
A. Marku, Lorenzo Da Dalt, A. Galli, et al.
Metabolism (2022) Vol. 136, pp. 155291-155291
Closed Access | Times Cited: 23
A. Marku, Lorenzo Da Dalt, A. Galli, et al.
Metabolism (2022) Vol. 136, pp. 155291-155291
Closed Access | Times Cited: 23
Showing 23 citing articles:
Targeting PCSK9 to tackle cardiovascular disease
Sandra Hummelgaard, Joachim Vilstrup, Camilla Gustafsen, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108480-108480
Open Access | Times Cited: 50
Sandra Hummelgaard, Joachim Vilstrup, Camilla Gustafsen, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108480-108480
Open Access | Times Cited: 50
Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization
Silvia Pelucchi, Lorenzo Da Dalt, Giulia De Cesare, et al.
Pharmacological Research (2025), pp. 107652-107652
Open Access | Times Cited: 1
Silvia Pelucchi, Lorenzo Da Dalt, Giulia De Cesare, et al.
Pharmacological Research (2025), pp. 107652-107652
Open Access | Times Cited: 1
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
Stefano Carugo, Cesare R. Sirtori, Alberto Corsini, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 12, pp. 995-1004
Open Access | Times Cited: 30
Stefano Carugo, Cesare R. Sirtori, Alberto Corsini, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 12, pp. 995-1004
Open Access | Times Cited: 30
Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms
Elena Osto, Fabrizia Bonacina, Angela Pirillo, et al.
Pharmacological Research (2023) Vol. 188, pp. 106667-106667
Open Access | Times Cited: 17
Elena Osto, Fabrizia Bonacina, Angela Pirillo, et al.
Pharmacological Research (2023) Vol. 188, pp. 106667-106667
Open Access | Times Cited: 17
Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic β-cells
Zhiyan Zhang, Huadong Zheng, Lusha Zhang, et al.
Islets (2025) Vol. 17, Iss. 1
Open Access
Zhiyan Zhang, Huadong Zheng, Lusha Zhang, et al.
Islets (2025) Vol. 17, Iss. 1
Open Access
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies
Lorenzo Da Dalt, Andrea Baragetti, Giuseppe Danilo Norata
Expert Opinion on Therapeutic Targets (2025)
Closed Access
Lorenzo Da Dalt, Andrea Baragetti, Giuseppe Danilo Norata
Expert Opinion on Therapeutic Targets (2025)
Closed Access
Neuronal PCSK9 Regulates Cognitive Performances via the Modulation of ApoER2 Synaptic Localization
Silvia Pelucchi, Lorenzo Da Dalt, Giulia De Cesare, et al.
(2025)
Closed Access
Silvia Pelucchi, Lorenzo Da Dalt, Giulia De Cesare, et al.
(2025)
Closed Access
Cholesterol Redistribution in Pancreatic β-Cells: A Flexible Path to Regulate Insulin Secretion
A. Galli, Anoop Arunagiri, Nevia Dule, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 224-224
Open Access | Times Cited: 9
A. Galli, Anoop Arunagiri, Nevia Dule, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 224-224
Open Access | Times Cited: 9
MRG15 aggravates sepsis-related liver injury by promoting PCSK9 synthesis and secretion
Boyuan Gu, Yu Jiang, Zhiwei Huang, et al.
International Immunopharmacology (2024) Vol. 140, pp. 112898-112898
Open Access | Times Cited: 3
Boyuan Gu, Yu Jiang, Zhiwei Huang, et al.
International Immunopharmacology (2024) Vol. 140, pp. 112898-112898
Open Access | Times Cited: 3
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9
Alexander M. Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 10
Closed Access | Times Cited: 2
Alexander M. Cao Zhang, Efthymios Ziogos, Tarek Harb, et al.
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 10
Closed Access | Times Cited: 2
Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing
Jianjun Gao, Fang-Yuan Wu, Yujia Liu, et al.
Science China Life Sciences (2024)
Closed Access | Times Cited: 2
Jianjun Gao, Fang-Yuan Wu, Yujia Liu, et al.
Science China Life Sciences (2024)
Closed Access | Times Cited: 2
PCSK9 in metabolism and diseases
Amir Ajoolabady, Domenico Praticò, Mohsen Mazidi, et al.
Metabolism (2024) Vol. 163, pp. 156064-156064
Closed Access | Times Cited: 2
Amir Ajoolabady, Domenico Praticò, Mohsen Mazidi, et al.
Metabolism (2024) Vol. 163, pp. 156064-156064
Closed Access | Times Cited: 2
PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
G Päth, Nikolaos Perakakis, Christos S. Mantzoros, et al.
Lipids in Health and Disease (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 9
G Päth, Nikolaos Perakakis, Christos S. Mantzoros, et al.
Lipids in Health and Disease (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
Erica Gianazza, Chiara Macchi, Cristina Banfi, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 5
Erica Gianazza, Chiara Macchi, Cristina Banfi, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 5
Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations
Fengyuan Lu, En Li, Xiaoyu Yang
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Fengyuan Lu, En Li, Xiaoyu Yang
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Multi-omic human pancreatic islet endoplasmic reticulum and cytokine stress response mapping provides type 2 diabetes genetic insights
Eishani Kumar Sokolowski, Romy Kursawe, Vijay Selvam, et al.
Cell Metabolism (2024) Vol. 36, Iss. 11, pp. 2468-2488.e7
Open Access | Times Cited: 1
Eishani Kumar Sokolowski, Romy Kursawe, Vijay Selvam, et al.
Cell Metabolism (2024) Vol. 36, Iss. 11, pp. 2468-2488.e7
Open Access | Times Cited: 1
Lipid Dynamics in Pancreatic β-Cells: Linking Physiology to Diabetes Onset
Blanka Holendová, Linda Stokičová, Lydie Plecitá‐Hlavatá
Antioxidants and Redox Signaling (2024) Vol. 41, Iss. 13-15, pp. 865-889
Closed Access | Times Cited: 1
Blanka Holendová, Linda Stokičová, Lydie Plecitá‐Hlavatá
Antioxidants and Redox Signaling (2024) Vol. 41, Iss. 13-15, pp. 865-889
Closed Access | Times Cited: 1
Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
Omonzejie E. Imaralu, Chandrakala Aluganti Narasimhulu, Pawan K. Singal, et al.
Canadian Journal of Physiology and Pharmacology (2023) Vol. 102, Iss. 01, pp. 14-25
Closed Access | Times Cited: 3
Omonzejie E. Imaralu, Chandrakala Aluganti Narasimhulu, Pawan K. Singal, et al.
Canadian Journal of Physiology and Pharmacology (2023) Vol. 102, Iss. 01, pp. 14-25
Closed Access | Times Cited: 3
The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
Fengyuan Lu, En Li, Xiaoyu Yang
Heliyon (2023) Vol. 9, Iss. 9, pp. e19371-e19371
Open Access | Times Cited: 3
Fengyuan Lu, En Li, Xiaoyu Yang
Heliyon (2023) Vol. 9, Iss. 9, pp. e19371-e19371
Open Access | Times Cited: 3
Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis and treatment
A. Galli, S. Moretti, Nevia Dule, et al.
AJP Endocrinology and Metabolism (2024) Vol. 327, Iss. 1, pp. E27-E41
Closed Access
A. Galli, S. Moretti, Nevia Dule, et al.
AJP Endocrinology and Metabolism (2024) Vol. 327, Iss. 1, pp. E27-E41
Closed Access
Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression
Frederick Berro Rivera, Sung Whoy, John Vincent Magalong, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 7, pp. 1103-1121
Closed Access
Frederick Berro Rivera, Sung Whoy, John Vincent Magalong, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 7, pp. 1103-1121
Closed Access
Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study
Simona Moffa, Teresa Mezza, Pietro Manuel Ferraro, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 1
Simona Moffa, Teresa Mezza, Pietro Manuel Ferraro, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 1
PCSK9 in extrahepatic tissues: What can we expect from its inhibition?
Angela Pirillo, Lâle Tokgözoğlu, Alberico L. Catapano
European Atherosclerosis Journal (2023) Vol. 2, Iss. 2, pp. 35-43
Open Access | Times Cited: 1
Angela Pirillo, Lâle Tokgözoğlu, Alberico L. Catapano
European Atherosclerosis Journal (2023) Vol. 2, Iss. 2, pp. 35-43
Open Access | Times Cited: 1
